mitoxantrone has been researched along with Guillain-Barre Syndrome in 1 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
Excerpt | Relevance | Reference |
---|---|---|
" Pediatric Multiple Sclerosis seems to respond better to immunosuppressant agents (Mitoxantrone, Cyclophosphamide, Natalizumab), as well as Neuromyelitis optica (Rituximab, Mycofenolate)." | 4.91 | The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data. ( Cocuzza, S; Di Mauro, P; Falsaperla, R; Ledda, C; Lubrano, R; Matin, N; Pavone, P; Serra, A; Tabatabaie, O; Vitaliti, G, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Vitaliti, G | 1 |
Tabatabaie, O | 1 |
Matin, N | 1 |
Ledda, C | 1 |
Pavone, P | 1 |
Lubrano, R | 1 |
Serra, A | 1 |
Di Mauro, P | 1 |
Cocuzza, S | 1 |
Falsaperla, R | 1 |
1 review available for mitoxantrone and Guillain-Barre Syndrome
Article | Year |
---|---|
The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.
Topics: Autoimmune Diseases; Child; Chorea; Cyclophosphamide; Guillain-Barre Syndrome; Humans; Immunoglobuli | 2015 |